A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of TGR-1202, a Novel PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Umbralisib (Primary) ; Chlorambucil; Obinutuzumab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 03 Sep 2019 Status changed from active, no longer recruiting to completed.
- 09 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Sep 2019.
- 19 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.